Business context and reporting period
This is IMARA Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2020, filed November 5, 2020. The request metadata names Enliven Therapeutics, Inc., but the filing identifies the registrant as IMARA Inc.; confirm the intended company before relying on this summary.
IMARA is a clinical-stage biopharmaceutical company developing IMR-687, an oral PDE9 inhibitor, for sickle cell disease (SCD) and beta-thalassemia. It has no approved products and reported no revenue.
Financial results and liquidity
| Metric | Q3 2020 | Q3 2019 | Nine months 2020 | Nine months 2019 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $9.5 million | $5.1 million | $23.2 million | $13.1 million |
| General and administrative expense | $3.0 million | $1.7 million | $7.0 million | $3.6 million |
| Net loss | $12.4 million | $6.6 million | $29.8 million | $16.2 million |
| Net loss per common share | $0.72 | $9.43 | $2.97 | $23.08 |
Margins are not meaningful because the company had no revenue. Nine-month operating cash use was $29.1 million, versus $13.8 million in 2019. Investing activities used $37.9 million, principally reflecting purchases of short-term investments; financing provided $96.3 million, including IPO proceeds and a Series B preferred-stock financing.
At September 30, 2020, cash and cash equivalents were $34.2 million and short-term investments were $61.9 million, totaling $96.1 million. Current assets were $99.7 million against current liabilities of $5.3 million. Total liabilities were $5.5 million; the filing reports no credit facility or committed capital source. Accumulated deficit was $84.6 million.
Material changes versus prior period
- Q3 operating expenses rose $5.6 million year over year; R&D increased $4.4 million, largely from IMR-687 clinical development, manufacturing, and trial costs. G&A increased $1.2 million, including public-company costs and personnel expenses.
- Nine-month operating expenses increased $13.5 million year over year, and net loss increased $13.6 million.
- The March 2020 IPO and April overallotment generated approximately $76.5 million net proceeds. Preferred stock converted into common stock at the IPO; the company also completed a $17.1 million net Series B financing in February. Common shares outstanding were 17.4 million at September 30.
- Nine-month 2020 common-stockholder loss included a $7.9 million preferred-stock beneficial-conversion-feature accretion, a noncash deemed dividend; this made loss attributable to common stockholders $37.7 million versus net loss of $29.8 million.
Outlook, commentary, and risks
- Management expected top-line Phase 2a SCD data in late Q4 2020 and additional open-label-extension data in Q1 2021. Interim data from Phase 2b trials in SCD and beta-thalassemia were expected in the second half of 2021. These are forward-looking expectations, not reported results.
- Management stated in the MD&A that available cash, cash equivalents, and investments were expected to fund operations into mid-2022. The liquidity note gives a less specific statement that resources should cover at least twelve months from filing. Both estimates depend on assumptions and may change; additional funding will be needed.
- COVID-19 had caused missed or incomplete Phase 2a patient visits, site-activation and enrollment delays in Phase 2b, and delays in regulatory-submission review. Further disruption could delay development and increase costs.
- Key risks include dependence on IMR-687, clinical and regulatory uncertainty, patient-enrollment challenges, reliance on third-party manufacturers and trial contractors, competition, intellectual-property protection, and the need for additional capital. The company reported no material pending or threatened legal proceedings and no off-balance-sheet arrangements.
- An exploratory analysis presented in October 2020 reported changes in cardiovascular-risk biomarker NT-ProBNP in a small trial-data analysis. The filing characterizes these findings as exploratory; they do not establish clinical benefit.
Most important facts for investors to verify
- Confirm that IMARA Inc., rather than Enliven Therapeutics, is the intended registrant.
- Check subsequent filings for final Phase 2a results and whether stated Phase 2b and extension-study timelines were achieved.
- Reconcile the runway language: mid-2022 in MD&A versus at least twelve months from filing in the liquidity note, and assess burn-rate assumptions.
- Review trial data, endpoint selection, safety, enrollment progress, and the significance of the exploratory NT-ProBNP findings.
- Monitor future financing needs, dilution risk, and progress toward additional sources of capital.